公开(公告)号：EP1140141A2

公开(公告)日：2001-10-10

申请号：EP99968968.0

申请日：1999-12-28

申请人： CHIRON CORPORATION

发明人： CHU,Keting ,  XIN, Hong ,  CHAN, Vivien, W., F. ,  KOTHAKOTA, Srinivas ,  WILLIAMS, Lewis, T. ,  WINTER, Jill, A.

IPC分类号： A61K38/19 ,  A61K48/00 ,  A61P35/00

CPC分类号： A61K38/195 ,  A61K38/2013 ,  A61K2300/00

摘要： The invention is based on the novel observation, reported herein, that SLC inhibits the growth of tumors in vivo and is a potent chemokine for Dendritic Cells (DC). Thus, the invention provides a method of treating cancer or hyperproliferative disorder in a mammalian subject, comprising: administering a therapeutically effective amount of an SLC to said subject. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids. The methods of the invention are useful in the treatment of cancer and hyperproliferative disorders. In addition, the invention provides methods for modulating dendritic cell function in a mammal, said method comprising administering a therapeutically effective amount of an SLC agent to said mammal, said agent selected from the group consisting of: SLC plypeptides, SLC polypeptide variants, SLC polypeptide fragments, polynucleotides encoding SLC polypeptides, variants and fragments, anti-SLC antibodies and ligands for the CCR7 receptor. Such methods can be used to increase or decrease an immune response, particularly a primary immune response, in a mammal. The methods are particularly useful in the prevention of graft rejection and in the treatment of autoimmune disease. Alternatively, the methods may be used to enhance an immune response.